Diadema Partners LP Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Diadema Partners LP acquired a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 42,081 shares of the company's stock, valued at approximately $351,000. Diadema Partners LP owned approximately 0.08% of Zevra Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Zevra Therapeutics by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock worth $23,554,000 after purchasing an additional 68,151 shares during the last quarter. Altium Capital Management LLC boosted its stake in Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock valued at $15,429,000 after acquiring an additional 150,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after acquiring an additional 144,256 shares in the last quarter. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the 4th quarter worth about $6,577,000. Finally, State Street Corp lifted its position in shares of Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company's stock worth $5,363,000 after purchasing an additional 52,966 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded down $0.04 during midday trading on Friday, hitting $7.20. 381,265 shares of the company's stock were exchanged, compared to its average volume of 612,115. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a market cap of $393.69 million, a P/E ratio of -3.65 and a beta of 1.94. The stock's 50 day moving average price is $7.52 and its 200-day moving average price is $8.12.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. Equities research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ZVRA shares. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research report on Wednesday, March 12th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $22.29.

Insider Buying and Selling

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 61,273 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the sale, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. The trade was a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 over the last quarter. Corporate insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.